Levosimendan protects against ischemia - reperfusion injury in the human heart muscle. A pilot study

Autor: Marcin Kunecki, Tomasz Oleksy, Jerzy Nozynski, Piotr Podolec, Jolanta Biernat, Marek Andrzej Deja, Krzysztof Stanislaw Golba, Wojciech Plazak

The consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b4971c96a665d079c7698c3e3674f1d
https://ruj.uj.edu.pl/xmlui/handle/item/306156

Effects of endogenous cardioprotective mechanisms on ischemia-reperfusion injury

Autor: Krzysztof S. Gołba, Piotr Podolec, Wojciech Płazak, Marcin Kunecki

Publikováno v: Postępy Higieny i Medycyny Doświadczalnej, Vol 71, Iss 1, Pp 20-31 (2017)

Ischemic heart disease have been remarked as a leading cause of morbidity and mortality in adults. Early restoration of cardiac perfusion is necessary to restore perfusion of ischemic heart muscle. Effective revascularization reduce mortality by limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::111ba319eb09e44c78b1c0f90bb370cb
http://phmd.pl/gicid/01.3001.0010.3786

Spontaneous pneumothorax (RCD code : vIII)

Autor: Marcin Kunecki, Adrian Rybski, Wojciech Płazak, Dominik Gałuszka

Pneumothorax is defined as the occurrence of air in the pleural space. From a clinical standpoint, pneumothorax can be classified as spontaneous (without an obvious triggering factor) or nonspontaneous. Primary spontaneous pneumothorax (PSP) is defin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::908e36a047c5c0a5dc3bfe3a2ee18341
https://ruj.uj.edu.pl/xmlui/handle/item/143756

‘Opioidergic postconditioning’ of heart muscle during ischemia/reperfusion injury

Autor: Jolanta Biernat, Wojciech Płazak, Krzysztof S. Gołba, Tomasz Roleder, Piotr Podolec, Marcin Kunecki, Tomasz Oleksy

Background: Ischemic preconditioning and postconditioning are the novel strategies of attaining cardioprotection against ischemia/reperfusion (I/R) injury. Previous studies suggested the role of opioid pathway, however the class of opioid receptors r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91fde954cc3befa401c88a729c7c6a4
https://ruj.uj.edu.pl/xmlui/handle/item/259075

Liraglutide and cardiovascular outcomes in type 2 diabetes

Autor: Robert Cuddihy, Rebeca Reyes-Garcia, Eduardo Hernández Salazar, Pawel Bogdanski, Tanja Milicic, Mihaela Vladu, Farida Valeeva, Silvio Buscemi, Veroniek Harbers, Thomas Pieber, Jeppe Gram, Martin Haluzik, Søren Gregersen, Ismet Tamer, Prasad Gunasekaran, Jean O'Connell, Peter Lommer Kristensen, Mustafa Kemal BALCI, Robert Lindsay, Hans Prozesky, JOSE ITALO MOTA, Dilek Gogas Yavuz, Pavel Trachta, Katerina Anderlova, Lise Tarnow, Paramesh S, Miguel Camafort-Babkowski, Selcuk Dagdelen, Shu-Fu Lin, Jarmila Krizova, İSMAİL ENGİN, Marcin Kunecki, Renan Montenegro Junior, Hayriye Esra Ataoglu, IREM DINÇER, John Buse, Jose Sgarbi, Christopher Gilfillan, Tatiana Kiseleva, Henna Cederberg, Sadi Ozdem, Chung-Huei Huang, Miljanka Vuksanovic, Sten Madsbad, Milan Piya, Patrick English, Yu-Yao Huang, Monika Zurawska-Klis, Alan Jaap, Alessandro Mattina, MARIANNA MARANGHI

Publikováno v: New England Journal of Medicine
Jaap, A 2016, ' Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes ', New England Journal of Medicine, vol. 375, no. 4, pp. 311-322 . https://doi.org/10.1056/NEJMoa1603827
Marso, S P, Daniels, G H, Brown-Frandsen, K, Kristensen, P, Mann, J F E, Nauck, M A, Nissen, S E, Pocock, S, Poulter, N R, Ravn, L S, Steinberg, W M, Stockner, M, Zinman, B, Bergenstal, R M, Buse, J B, LEADER Steering Committee & Hegedüs, L 2016, ' Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes ', The New England Journal of Medicine, vol. 375, no. 4, pp. 311-322 . https://doi.org/10.1056/NEJMoa1603827

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and hi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3beb7f3304e6b754eeb3ba9c143961e
http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/417